Bioarctic AB has entered into a research and collaboration agreement with Eli Lilly and Co. on a new treatment in the field of neurodegeneration. The collaboration will see Bioarctic generate a new drug candidate combining its Braintransporter technology with an undisclosed Lilly molecule.
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as AP2-associated protein kinase 1 (AAK1) inhibitors that are potentially useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s disease, diabetic peripheral neuropathy, postherpetic neuralgia (PHN) and schizophrenia.
Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.
Alturos Therapeutics BV has advanced its lead candidate, ALT-0135, into IND-enabling studies. Alturos is targeting the earliest toxic triggers in Alzheimer’s disease, particularly protein oligomers that drive synaptic loss and neuronal death.
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive allosteric modulator under development for the treatment of severe pediatric epilepsies.
Cenna Biosciences Inc. has obtained IND clearance from the FDA for 8M2D, a first-in-class peptide for the treatment of Alzheimer’s disease. A phase Ia/Ib trial of 8M2D in healthy volunteers and patients with early Alzheimer’s disease is expected to begin dosing late this year.
Ignis Therapeutics (Suzhou) Co. Ltd. has synthesized new tetrahydroisoquinoline compounds acting as dopamine D1 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of apathy, Parkinson’s disease, Huntington’s disease, dystonia, Alzheimer’s disease, neuropathic pain, psychosis and sleep disorder and among others.
Vedana Therapeutics has emerged from stealth with $46 million in series A financing. The company is developing next-generation, preventive therapies for migraine by leveraging pituitary adenylate cyclase-activating polypeptide (PACAP) biology, and highly selective combinatorial targeting of clinically validated pathways.
Acumen Pharmaceuticals Inc. has nominated ACU-301 and ACU-401 as development candidates in its Enhanced Brain Delivery (EBD) program as treatments for Alzheimer’s disease.
RSS
